STACKD summary
Limited human dataSemax, Selank, and Noopept: the Russian nootropic peptides
Decades of domestic clinical use, but almost no independent international replication.
Plain-language summary
Semax, Selank, and Noopept are the three peptides most often grouped together as “Russian nootropics.” All three were developed by Russian research institutes, are registered as prescription drugs in Russia for specific neurological or psychiatric indications, and have real human trial data behind them, Semax for stroke recovery, Selank for generalized anxiety, Noopept for post-stroke and post-injury cognitive impairment. The honest caveat: almost all of that trial data comes from a small number of Russian research groups, using study designs (open-label, unblinded, or small-sample) that would be considered preliminary by international standards, and none has been through the kind of large, independent, multinational replication that semaglutide or tirzepatide have.
What was studied
Human trials in clinical (not healthy-volunteer) populations: Semax in acute ischemic stroke and optic nerve conditions; Selank in generalized anxiety disorder and neurasthenia, compared against benzodiazepines; Noopept in post-stroke and post-traumatic mild cognitive impairment, compared against piracetam.
Key takeaways
- All three have decades of domestic (Russian) prescription use for specific neurological/psychiatric conditions, which is more real-world human exposure than most “research peptides” in this space.
- Selank's anxiolytic effect in trials was reported as comparable to benzodiazepines like medazepam and phenazepam, without the sedation or dependence typically associated with that drug class.
- Semax's stroke trials measured a hard clinical endpoint (neurological deficit progression), not just a subjective cognitive-enhancement claim.
- Noopept was tested in patients recovering from brain injury or stroke, not in healthy people seeking cognitive enhancement, a meaningfully different population than most online use cases.
Limitations & what we don't know
- Trial designs are frequently open-label or non-randomized rather than double-blind, placebo-controlled RCTs by modern international standards.
- Nearly all of the literature for all three compounds comes from overlapping Russian research groups, with little independent Western replication.
- None of the three is FDA-approved; none has gone through a large multinational phase 3 program.
- Trial populations are stroke, anxiety-disorder, or brain-injury patients, not healthy people optimizing cognition, which is how these are mostly discussed online.
Sources
Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.